Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:46:41.689Z.
Calculation as of: 2026-10-06T12:46:41.689Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 463be1a1b995a1dfb9509f80aff3bd03150ce45d2105de53d296fe87a8cca28c
PE RATIO
N/A
Market Cap
$118.50M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.24M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.17M
PE Ratio
N/A
TTM Avg
17.69
3Y Avg
17.69
5Y Avg
17.69
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $117.43M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $116.59M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $118.63M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | N/A | 17.69 | 17.69 | 17.69 |
| Immunic, Inc. (IMUX)vs › | $109.93M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.00
Forward EPS (Est.)
$-0.91
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
